M&A

Even More Woes for Illumina’s Proposed Acquisition of Grail
Even More Woes for Illumina’s Proposed Acquisition of Grail
Medical Devices and Diagnostics Industry
Illumina
Grail
M&A
diagnostics
FTC
Flag link:
Vertex puts a blockbuster valuation on its CRISPR deal
Vertex puts a blockbuster valuation on its CRISPR deal
EP Vantage
Vertex Pharmaceuticals
CRISPR Therapeutics
CRISPR
gene editing
CTX001
M&A
Flag link:
Virtual Surgical to Go Public Through Merger with D8 Holdings
Virtual Surgical to Go Public Through Merger with D8 Holdings
Medical Devices and Diagnostics Industry
Virtual Surgical
D8 Holdings
M&A
devices
robotic surgery
Flag link:
Surprise: AstraZeneca's $39B Alexion buy clears a newly vigilant FTC without a hitch
Surprise: AstraZeneca's $39B Alexion buy clears a newly vigilant FTC without a hitch
Fierce Pharma
AstraZeneca
Alexion
M&A
FTC
Flag link:
In one of their first ever acquisitions, Relay bets $85M cash on a new AI-based screening approach
In one of their first ever acquisitions, Relay bets $85M cash on a new AI-based screening approach
Endpoints
Relay Therapeutics
M&A
ZebiAI
artificial intelligence
drug discovery
Flag link:
Another big CRO deal in the works? Thermo Fisher in talks to acquire PPD for $15B+ — report
Another big CRO deal in the works? Thermo Fisher in talks to acquire PPD for $15B+ — report
Endpoints
ThermoFisher Scientific
PPD
M&A
CROs
Flag link:
Quiet times return for biopharma takeouts
Quiet times return for biopharma takeouts
EP Vantage
M&A
Alexion
Amgen
AstraZeneca
Biogen
Five Prime Therapeutics
Gilead Sciences
GW Pharma
Horizon Therapeutics
Immunomedics
Jazz Pharmaceutical
Kymab
Merck
Pandion
Sanofi
Viela Bio
Flag link:
Diasorin heads to the US with $1.8bn Luminex deal
Diasorin heads to the US with $1.8bn Luminex deal
EP Vantage
Diasorin Molecular
Luminex
diagnostics
M&A
COVID-19
Flag link:
Sanofi spends $160M in bet that Tidal’s tech gets it to off-the-shelf CAR-T therapy
Sanofi spends $160M in bet that Tidal’s tech gets it to off-the-shelf CAR-T therapy
MedCity News
Sanofi
M&A
Tidal Therapeutics
CAR-T
MRNA
Flag link:
Could Illumina's Quest to Acquire GRAIL Fail?
Could Illumina's Quest to Acquire GRAIL Fail?
Motley Fool
Illumina
Grail
M&A
liquid biopsies
diagnostics
Flag link:
Hologic Locks Down 4th M&A Target This Year
Hologic Locks Down 4th M&A Target This Year
Medical Devices and Diagnostics Industry
Hologic
devices
M&A
Mobidiag Oy
molecular diagostics
Flag link:
Invitae borrows against the future
Invitae borrows against the future
EP Vantage
Invitae
cancer
liquid biopsy
M&A
Flag link:
An antitrust expert weighs in on the FTC’s complaint against Illumina
An antitrust expert weighs in on the FTC’s complaint against Illumina
Stat
Illumina
Grail
M&A
antitrust
FTC
Flag link:
Audentes CEO exits as Astellas rebrands a gene therapy buyout
Audentes CEO exits as Astellas rebrands a gene therapy buyout
BioPharma Dive
Astellas
Audentes
gene therapy
M&A
Astellas Gene Therapies
Flag link:
Takeda Pharmaceutical concludes sale of OTC and non-core assets to Orifarm for $670m
Takeda Pharmaceutical concludes sale of OTC and non-core assets to Orifarm for $670m
Pharmaceutical Business Review
Takeda
OTC
M&A
Orifarm
Flag link:
Drugmaker Bausch to sell stake in Egypt's Amoun Pharma for $740 million
Drugmaker Bausch to sell stake in Egypt's Amoun Pharma for $740 million
Reuters
Bausch Health
Amoun
ADQ
M&A
Flag link:
Illumina Stock Tumbles As FTC Moves To Block $7.1 Billion Grail Acquisition
Illumina Stock Tumbles As FTC Moves To Block $7.1 Billion Grail Acquisition
Investors Business Daily
Illumina
FTC
Grail
M&A
liquid biopsy
Flag link:
Amgen drops $55M upfront for Rodeo Therapeutics and its prostaglandin blockers
Amgen drops $55M upfront for Rodeo Therapeutics and its prostaglandin blockers
Fierce Biotech
Amgen
Rodeo Therapeutics
M&A
Flag link:
Why Roche's $1.8 Billion Acquisition of GenMark Is a Smart Move
Why Roche's $1.8 Billion Acquisition of GenMark Is a Smart Move
Motley Fool
Roche
GenMark
M&A
Flag link:
Fidia Farmaceutici acquires Sanofi’s anti-inflammatory drugs portfolio
Fidia Farmaceutici acquires Sanofi’s anti-inflammatory drugs portfolio
Pharmaceutical Business Review
Sanofi
Fidia Farmaceutici
M&A
anti-inflammatories
Flag link:

Pages